Related Experiment Video

Updated: Jun 7, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K

Inhibition of peritendinous adhesion through targeting JAK2-STAT3 signaling pathway: The therapeutic potential of

Xue Fang1, Wang Zhang1, Changhuan Liu1

  • 1Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China; Hubei Clinical Medical Research Center of Trauma and Microsurgery, Wuhan, Hubei, China.

International Immunopharmacology
|November 11, 2024
PubMed

Insights

The JAK2-STAT3 pathway inhibitor AG490 effectively reduced fibroblast proliferation and migration, mitigating fibrosis and inflammation in tendon injury models. This presents AG490 as a promising treatment for preventing peritendinous adhesions.

Area of Science:

  • Biomedical Science
  • Cell Biology
  • Regenerative Medicine

Background:

  • Peritendinous adhesion, a common complication after tendon repair, stems from excessive collagen deposition driven by fibroblast proliferation in an inflammatory state.
  • The Janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3) pathways are implicated in fibrosis but their role in peritendinous adhesion is not fully understood.

Purpose of the Study:

  • To investigate the role of the JAK2-STAT3 signaling pathway in peritendinous adhesion fibrosis.
  • To evaluate the therapeutic potential of the JAK2/STAT3 pathway inhibitor AG490 in preventing peritendinous adhesions.

Main Methods:

  • Observed p-JAK2 and p-STAT3 protein levels in human and rat peritendinous adhesion models.
  • Utilized in vitro assays (fibroblast proliferation, migration) and in vivo studies in a rat tendon injury model.
  • Administered the JAK2/STAT3 inhibitor AG490 to assess its effects on cellular processes and tissue formation.

Main Results:

  • p-JAK2 and p-STAT3 were upregulated in peritendinous adhesion specimens and models.
  • AG490 inhibited TGF-β1-induced fibroblast proliferation and migration in vitro.
  • AG490 reduced pro-inflammatory factors (IL-1β, TNF-α) and extracellular matrix (ECM) deposition in vitro and in vivo.
  • Histological analysis confirmed AG490's prevention of fibrous tissue formation in a rat tendon injury model.

Conclusions:

  • The JAK2-STAT3 signaling pathway plays a significant role in the development of peritendinous adhesion fibrosis.
  • AG490 demonstrates efficacy in inhibiting fibrosis and inflammation by targeting the JAK2-STAT3 pathway.
  • AG490 represents a potential therapeutic strategy for the prophylaxis of peritendinous adhesions.
Keywords:
AG490JAK2-STAT3 signaling pathwayPeritendinous adhesionProliferation

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.1K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

995

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
2.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K